Title:
NK3 ANTAGONISTS FOR TREATING PATIENTS HAVING LOW ESTROGEN
Document Type and Number:
WIPO Patent Application WO/2023/147134
Kind Code:
A3
Abstract:
The present disclosure relates generally to a method of treating post-traumatic stress disorder, schizophrenia, acute stress disorder, anxiety, depression, or bone loss comprising administration of a neurokinin (NK) receptor antagonist to a patient.
More Like This:
Inventors:
SCHELLING D CHRISTOPHER (US)
Application Number:
PCT/US2023/011890
Publication Date:
August 31, 2023
Filing Date:
January 30, 2023
Export Citation:
Assignee:
ACER THERAPEUTICS INC (US)
International Classes:
A61K31/4545; A61K31/47; A61K31/4985; A61K31/5383; A61K45/06; A61P15/00; A61P25/00; A61P25/18; A61P25/22; A61P25/24; A61P35/00; A61P43/00
Domestic Patent References:
| WO2016146712A1 | 2016-09-22 | |||
| WO2022026900A2 | 2022-02-03 | |||
| WO2022026901A2 | 2022-02-03 |
Other References:
PANAY NICHOLAS ET AL: "Elinzanetant (NT-814): a novel, non-hormonal dual NK-1,3 receptor antagonist for the treatment of vasomotor symptoms - key findings from the Phase 2 SWITCH-1 study", MATURITAS, ELSEVIER, AMSTERDAM, NL, vol. 152, 1 October 2021 (2021-10-01), pages 71, XP086833988, ISSN: 0378-5122, [retrieved on 20211018], DOI: 10.1016/J.MATURITAS.2021.08.018
PATEL BIJAL ET AL: "Menopause review: Emerging treatments for menopausal symptoms", BAILLIERE'S BEST PRACTICE AND RESEARCH. CLINICAL OBSTETRICS ANDGYNAECOLOGY, BAILLIERE TINDALL, LONDON, GB, vol. 81, 17 November 2021 (2021-11-17), pages 134 - 144, XP087053991, ISSN: 1521-6934, [retrieved on 20211117], DOI: 10.1016/J.BPOBGYN.2021.10.010
"P144:PSYCHOMOTOR AND COGNITIVE EFFECTS OF ASINGLE ORAL DOSE OF SB223412 IN HEALTHY VOLUNTEERS COMPARED TO PLACEBO OR HALOPERIDOL", BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, NORDIC PHARMACOLOGICAL SOCIETY, COPENHAGEN, DK, vol. 101, 3 August 2007 (2007-08-03), pages 103 - 157, XP072366953, ISSN: 1742-7835, DOI: 10.1111/J.1742-7843.2007.00104.X
DAVIS SUSAN R ET AL: "Treating menopause - MHT and beyond", NATURE REVIEWS. ENDOCRINOLOGY, NATURE PUBL. GROUP, US, vol. 18, no. 8, 27 May 2022 (2022-05-27), pages 490 - 502, XP037900424, ISSN: 1759-5029, [retrieved on 20220527], DOI: 10.1038/S41574-022-00685-4
PATEL BIJAL ET AL: "Menopause review: Emerging treatments for menopausal symptoms", BAILLIERE'S BEST PRACTICE AND RESEARCH. CLINICAL OBSTETRICS ANDGYNAECOLOGY, BAILLIERE TINDALL, LONDON, GB, vol. 81, 17 November 2021 (2021-11-17), pages 134 - 144, XP087053991, ISSN: 1521-6934, [retrieved on 20211117], DOI: 10.1016/J.BPOBGYN.2021.10.010
"P144:PSYCHOMOTOR AND COGNITIVE EFFECTS OF ASINGLE ORAL DOSE OF SB223412 IN HEALTHY VOLUNTEERS COMPARED TO PLACEBO OR HALOPERIDOL", BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, NORDIC PHARMACOLOGICAL SOCIETY, COPENHAGEN, DK, vol. 101, 3 August 2007 (2007-08-03), pages 103 - 157, XP072366953, ISSN: 1742-7835, DOI: 10.1111/J.1742-7843.2007.00104.X
DAVIS SUSAN R ET AL: "Treating menopause - MHT and beyond", NATURE REVIEWS. ENDOCRINOLOGY, NATURE PUBL. GROUP, US, vol. 18, no. 8, 27 May 2022 (2022-05-27), pages 490 - 502, XP037900424, ISSN: 1759-5029, [retrieved on 20220527], DOI: 10.1038/S41574-022-00685-4
Attorney, Agent or Firm:
TANNER, Lorna L. et al. (US)
Download PDF:
Previous Patent: LIQUID BIOPSY ANALYTES TO DEFINE CANCER STAGES
Next Patent: NK RECEPTOR ANTAGONISTS FOR TREATMENT OF PROSTATE CANCER
Next Patent: NK RECEPTOR ANTAGONISTS FOR TREATMENT OF PROSTATE CANCER